<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00443430</url>
  </required_header>
  <id_info>
    <org_study_id>R01AR049762</org_study_id>
    <secondary_id>5R01AR049762-02</secondary_id>
    <nct_id>NCT00443430</nct_id>
  </id_info>
  <brief_title>Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis</brief_title>
  <official_title>Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis (TREAT in JIA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two aggressive drug regimens for children with
      poly-juvenile idiopathic arthritis (JIA) and extended oligo JIA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      JIA is a type of arthritis with no definite cause and an onset prior to 16 years of age. JIA
      causes joint destruction, pain, and permanent disability. There are multiple types of JIA;
      collectively, they represent one of the most common chronic diseases in children and the most
      prevalent pediatric rheumatic illness. Poly-JIA, one type of JIA, affects at least five
      joints in the body within the first 6 months of disease. Long-term remission of poly-JIA is
      uncommon, and most children must remain on multiple combinations of medications for many
      years. The usual treatment for poly-JIA is based upon the gradual addition of medications
      that might be more effective in treating this disease. There is a need to find uniformly
      effective treatments for children with poly-JIA. Based on previous adult arthritis studies,
      there appears to be an early window of opportunity in the disease progression during which
      aggressive therapy has a profound beneficial long-term effect. The purpose of this study is
      to compare the effectiveness of two aggressive drug regimens in treating children with
      poly-JIA. Specifically, the study will determine whether aggressive therapy started in the
      first 6 months of disease onset can result in inactive disease and clinical remission while
      on these medications.

      All participants will receive weekly methotrexate shots while in the study. In addition,
      participants will be randomly assigned to one of two groups:

        -  Group 1 participants will receive placebo etanercept shots for up to 12 months and daily
           placebo prednisolone liquid for 4 months.

        -  Group 2 participants will receive etanercept shots for up to 12 months and daily
           prednisolone liquid for 4 months.

      The study will last up to 12 months and include two parts. Part A will last 1 to 6 months,
      depending on response to assigned treatments. If participants are still experiencing active
      arthritis at 6 months, they will be offered open-label treatment with etanercept and
      prednisolone. If participants experience inactive disease any time prior to 6 months, they
      will enter Part B of the study. During Part B, which will last up to 6 months, participants
      will remain on the same treatment regimen that they were provided in Part A. If participants
      experience inactive disease followed by a flare of disease any time during the study, they
      will stop participating.

      During the study, there will be 11 study visits for all participants. Study visits will
      include a physical exam, including joint evaluations; blood and urine collection; and
      questionnaires regarding function, quality of life, medication compliance, other medications
      used, infections, and adverse symptoms.

      Blood will be collected for translational studies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants Who Attain Inactive Disease by 6 Months</measure>
    <time_frame>6 months after initiation of study intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Profiles, Including the Number of Treatment-emergent, Serious, or Unexpected Adverse Events and Other Important Medical Events</measure>
    <time_frame>Over 12 months maximum study participation per subject</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Remission on Medication</measure>
    <time_frame>12 months or end of study</time_frame>
    <description>6 months of clinical inactive disease</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Juvenile Chronic Polyarthritis</condition>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <condition>Juvenile Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Methotrexate Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus placebo etanercept and placebo prednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate-Etanercept-Prednisolone Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus etanercept 0.8 mg/kg given by subcutaneous injection once per week, plus prednisolone by mouth daily with decreasing dose tapered over 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus placebo etanercept and and placebo prednisolone</description>
    <arm_group_label>Methotrexate Arm</arm_group_label>
    <other_name>placebo enbrel</other_name>
    <other_name>placebo prednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate - etanercept - prednisolone arm</intervention_name>
    <description>methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus etanercept 0.8 mg/kg given by sub cutaneous injection once per week, plus prednisolone, by mouth daily with decreasing dose tapered over 16 weeks.</description>
    <arm_group_label>Methotrexate-Etanercept-Prednisolone Arm</arm_group_label>
    <other_name>enbrel</other_name>
    <other_name>prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of active poly-JIA as determined by International League of Associations for
             Rheumatology (ILAR) criteria

          -  Onset of signs and symptoms of poly-JIA for 12 months or less prior to study screening

          -  Willing to use acceptable forms of contraception for the duration of the study and for
             3 months after the study

          -  Parent or guardian willing to provide informed consent

          -  Able to attend all study visits

        Exclusion Criteria:

          -  Received or currently receiving disease-modifying antirheumatic drugs (DMARDs),
             biologic, or prednisone for any duration for treatment of poly-JIA, with the following
             exceptions:

               1. Methotrexate duration must be less than or equal to 6 weeks at a dose of less
                  than or equal to 0.5 mg/kg/week (40 mg max),

               2. Steroid use has been less than or equal to 4 weeks and the subject is off of
                  steroids for at least 1 week prior to enrollment

          -  Received intramuscular or soft-tissue injections of corticosteroids for treatment of
             poly-JIA before receiving the first dose of study medication. Up to 2 joint injections
             with intra-articular steroids (IAS) will be allowed up to 7 days after the baseline
             visit.

          -  History of or active cancer of any type

          -  Active gastrointestinal disease (e.g., inflammatory bowel disease)

          -  Chronic or acute kidney or liver disorder

          -  Significant blood clotting defect

          -  AST (SGOT), ALT (SGPT), or BUN levels more than two times the upper level of normal,
             creatinine levels more than 1.5 mg/dl, or any other laboratory abnormality considered
             to be clinically significant within 28 days prior to baseline

          -  Chronic condition (e.g., diabetes, epilepsy) that is either not stable or poorly
             controlled and may interfere with study participation

          -  Received any investigational medication within 30 days prior to the first dose of
             study medication or scheduled to receive an investigational drug (other than the study
             medications) during the course of the study

          -  Chronic or active infection or any major episode of infection requiring
             hospitalization or treatment with intravenous antibiotics within 30 days prior to
             study screening

          -  HIV infected

          -  Known past or current hepatitis infection

          -  Received a live virus vaccine within 1 month prior to baseline

          -  Purified protein derivative (PPD) positive (positive tuberculosis [TB] test)

          -  Pregnancy

          -  Any medical condition that would make study participation difficult or inadvisable in
             the opinion of the investigator

          -  History of or current psychiatric illness that would interfere with study
             participation

          -  History of alcohol or drug abuse within the 6 months prior to study entry that would
             interfere with study participation

          -  Inability to comply with study requirements for any reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol A. Wallace, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Childrens Hospital and Regional Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123-4282</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Hospital</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Health Science Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Scottish Rite Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital and Regional Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.carragroup.org</url>
    <description>Click here for the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Web site</description>
  </link>
  <reference>
    <citation>Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore JB, White B, Giannini EH; Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2006 Jun;54(6):1987-94.</citation>
    <PMID>16732547</PMID>
  </reference>
  <reference>
    <citation>Wallace CA. Current management of juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol. 2006 Apr;20(2):279-300. Review.</citation>
    <PMID>16546057</PMID>
  </reference>
  <reference>
    <citation>Wallace CA, Ruperto N, Giannini E; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004 Nov;31(11):2290-4.</citation>
    <PMID>15517647</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2007</study_first_submitted>
  <study_first_submitted_qc>March 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2007</study_first_posted>
  <results_first_submitted>March 13, 2013</results_first_submitted>
  <results_first_submitted_qc>May 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 31, 2013</results_first_posted>
  <last_update_submitted>May 30, 2013</last_update_submitted>
  <last_update_submitted_qc>May 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seattle Children's Hospital</investigator_affiliation>
    <investigator_full_name>Carol Wallace</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Childhood Arthritis</keyword>
  <keyword>Juvenile Arthritis</keyword>
  <keyword>Juvenile Arthritis Treatment</keyword>
  <keyword>Childhood Arthritis Drug Treatment</keyword>
  <keyword>Juvenile Arthritis Remission</keyword>
  <keyword>Inactive Disease in Juvenile Arthritis</keyword>
  <keyword>Childhood Polyarthritis</keyword>
  <keyword>Extended Oligoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>85 children with poly JIA within 12 months of onset recruited from pediatric rheumatology clinics at 15 sites</recruitment_details>
      <pre_assignment_details>Eligible patients were permitted to have received up to 2 intra-articular corticosteroid injections before or up to 2 weeks after baseline; and oral prednisolone for up to 4 weeks, but must have been off corticosteroids for at least 1 week prior to enrollment. Patients with past or current JIA-associated uveitis were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Methotrexate Arm</title>
          <description>Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus placebo etanercept and placebo prednisolone</description>
        </group>
        <group group_id="P2">
          <title>Methotrexate-Prednisolone-Etanercept Arm</title>
          <description>Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus etanercept 0.8 mg/kg given by subcutaneous injection once per week, plus prednisolone by mouth daily with decreasing dose tapered over 16 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>2 patients were ineligible</population>
      <group_list>
        <group group_id="B1">
          <title>Methotrexate Arm</title>
          <description>Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus placebo etanercept and placebo prednisolone</description>
        </group>
        <group group_id="B2">
          <title>Methotrexate-Prednisolone-Etanercept Arm</title>
          <description>Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus etanercept 0.8 mg/kg given by subcutaneous injection once per week, plus prednisolone by mouth daily with decreasing dose tapered over 16 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.1" spread="4.1"/>
                    <measurement group_id="B2" value="9.9" spread="4.6"/>
                    <measurement group_id="B3" value="10.5" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Participants Who Attain Inactive Disease by 6 Months</title>
        <time_frame>6 months after initiation of study intervention</time_frame>
        <population>all participants receiving study medications</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Arm</title>
            <description>Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus placebo etanercept and placebo prednisolone</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate-Prednisolone-Etanercept Arm</title>
            <description>Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus etanercept 0.8 mg/kg given by subcutaneous injection once per week, plus prednisolone by mouth daily with decreasing dose tapered over 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Who Attain Inactive Disease by 6 Months</title>
          <population>all participants receiving study medications</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Profiles, Including the Number of Treatment-emergent, Serious, or Unexpected Adverse Events and Other Important Medical Events</title>
        <time_frame>Over 12 months maximum study participation per subject</time_frame>
        <population>all participants that received study medications</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Arm</title>
            <description>Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus placebo etanercept and placebo prednisolone</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate-Prednisolone-Etanercept Arm</title>
            <description>Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus etanercept 0.8 mg/kg given by subcutaneous injection once per week, plus prednisolone by mouth daily with decreasing dose tapered over 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Profiles, Including the Number of Treatment-emergent, Serious, or Unexpected Adverse Events and Other Important Medical Events</title>
          <population>all participants that received study medications</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Remission on Medication</title>
        <description>6 months of clinical inactive disease</description>
        <time_frame>12 months or end of study</time_frame>
        <population>all participants receiving study medications</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate Arm</title>
            <description>Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus placebo etanercept and placebo prednisolone</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate-Prednisolone-Etanercept Arm</title>
            <description>Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus etanercept 0.8 mg/kg given by subcutaneous injection once per week, plus prednisolone by mouth daily with decreasing dose tapered over 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Remission on Medication</title>
          <description>6 months of clinical inactive disease</description>
          <population>all participants receiving study medications</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Methotrexate Arm</title>
          <description>Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus placebo etanercept and placebo prednisolone</description>
        </group>
        <group group_id="E2">
          <title>Methotrexate-Prednisolone-Etanercept Arm</title>
          <description>Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus etanercept 0.8 mg/kg given by subcutaneous injection once per week, plus prednisolone by mouth daily with decreasing dose tapered over 16 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>pneumonia</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <description>This participant withdrew from the study, the event resolved without sequelae</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title vocab="septic hop">septic hip</sub_title>
                <description>after discontinuation of open label therapy for 2 months, patient was found to have infection of the hip, this resolved. No organism was recovered.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title vocab="psychosis">psychosis</sub_title>
                <description>Participant on open label medications had acute psyhotic event that resolved with tapering of prednisolone. Patient continued in the study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>abnormal transaminas</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>liver function test elevation</sub_title>
                <description>elevation of LFT grade 3</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>small number of participants with recent onset poly JIA</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Carol Wallace, MD Principal Investigator</name_or_title>
      <organization>University of Washington and Seattle Children's Hospital</organization>
      <phone>206-987-2057</phone>
      <email>cwallace@u.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

